FDA expands Bravecto Quantum tick label for dogs

Merck Animal Health said the FDA has approved an expanded label for Bravecto Quantum, its long-acting fluralaner injection for dogs, adding 12-month treatment and control claims for the Asian longhorned tick (Haemaphysalis longicornis) and Gulf Coast tick (Amblyomma maculatum). The product was originally approved on July 10, 2025, as the first FDA-approved flea and tick drug for dogs with 8- to 12-month protection, depending on tick species. With this March 18, 2026 label expansion, Bravecto Quantum now carries 12-month claims for five tick species, while lone star tick coverage remains at 8 months. It remains indicated for dogs and puppies 6 months of age and older, and it must be prescribed and administered by a licensed veterinarian. (merck-animal-health-usa.com)

Why it matters: For veterinary professionals, the update broadens the label at a time when parasite risk is shifting geographically. USDA says the invasive Asian longhorned tick can establish large infestations and spread quickly because females can reproduce without mating, while the Gulf Coast tick is a recognized veterinary concern in dogs. The expanded label may make Bravecto Quantum more attractive in clinics looking for longer-duration compliance support, but veterinarians still need to match dosing intervals to local tick pressure because potential lone star tick exposure still requires redosing at 8 months. That distinction has also drawn outside scrutiny: in March 2026, BBB National Programs’ National Advertising Division said Merck should modify or discontinue some unqualified “once-a-year” tick-protection claims, though it found the company had support for a general safety claim. (aphis.usda.gov)

What to watch: Watch for how quickly practices adopt the expanded indication in endemic and emerging tick markets, and whether Merck changes marketing language as its appeal of the NAD decision moves forward. (bbbprograms.org)